CLINICAL Policies and Procedures

HOSPICE APPROVED MEDICATIONS

<table>
<thead>
<tr>
<th>NHPCO Standard(s):</th>
<th>Policy #: CP 222</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFC 4.5, PFC 6.3, CES 1.4, CES 4</td>
<td>BOD Approval/Review 03/21/17</td>
</tr>
</tbody>
</table>

| Regulatory Citation: | COPs 418.54(c)(6) and 106 |

POLICY

High Peaks Hospice (HPH) has developed a formulary of drugs that are appropriate for managing pain and symptoms related to the terminal illness. The drugs listed in Exhibit A are considered preferred drugs for HPH use.

HPH pays for medications related to the hospice diagnosis and for pain and symptom management for the terminal illness. Non-formulary drugs are considered for patients who fail with formulary drugs or for whom formulary drugs are contraindicated. Over the counter, non-prescription medications may be ordered, but are not approved for HPH payment unless they are related to the hospice diagnosis.

PROCEDURE

1. Before approving a drug for reimbursement by HPH, the following utilization review should be conducted:
   - Patient demographics
   - Hospice diagnosis
   - Past medical conditions
   - Medication the patient is currently taking/duplications
   - Drugs initiated since terminal illness
   - Appropriate therapy for this stage of patient’s illness
   - Goal of drug therapy/laboratory monitoring
   - Is the therapy effective/ineffective
   - Identification of potential adverse reactions

2. All medications approved for HPH reimbursement will be reviewed within 48 hours of admission, at each IDT for appropriateness for hospice care, and if an “Incident Report” or “Medication Incident Report” is completed.

3. Medications approved for hospice use have up to a thirty day maximum supply given at a time.

LAST REVIEW DATE: PCCs, IDT 1/4/17, Clinical Comm 2/7/17
LAST UPDATED: Comp Coord 10/03/16, 1/23/17, 02/1/17, 09/01/18
BOARD APPROVAL: March 21, 2017